Publication
Budget Impact of Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF) and Iron Deficiency in Switzerland.
Journal Paper/Review - Jun 10, 2022
Brock Elisabeth, Moschovitis Giorgio, Maeder Micha, Pfister Otmar
Units
PubMed
Doi
Contact
Citation
Brock E, Moschovitis G, Maeder M, Pfister O. Budget Impact of Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF) and Iron Deficiency in Switzerland. Pharmacoecon Open 2022; 6:735-743.
Type
Journal Paper/Review (English)
Journal
Pharmacoecon Open 2022; 6
Publication Date
Jun 10, 2022
Issn Electronic
2509-4254
Pages
735-743
Brief description/objective
A budget impact analysis compared treating patients with heart failure (HF) and reduced ejection fraction (HFrEF) and iron deficiency (ID) in Switzerland with intravenous ferric carboxymaltose (FCM) or placebo.